The study on the mechanism of antiangiogenesis and liver function evaluation of primary hepatocellular carcinoma in Guangxi
Abstract：Objective To explore the mechanism of antiangiogenesis and the evaluation of perioperative liver function in primary hepatocellular carcinoma in Guangxi. Methods The survival data of liver cancer patients were analyzed by molecular biology experiment,animal experiment and drug resistance experiment. A linear regression analysis was performed to observe the acoustic radiation force impulse(ARFI) score and postoperative standard residual liver volume(SRLV) in 104 patients with liver cancer. Preoperative urinary 8-hydroxydeoxyguanosine (8-OHdG) and peripheral blood T lymphocyte subgroup CD4 + and CD8 + expressions were detected. Results COX-2/PGE2 signaling pathways regulated VEGF activity via regulating HIF-2 α activity; PEG-SS-PLL effectively transfected the siVEGF,and its cytotoxicity was negligible,and the expressions of VEGF in mRNA and the protein levels significantly decreased both in vitro and in vivo,inhibiting tumor growth. The critical value of SRLV with severe compensation was 503 ml/m2. The linear regression equation of preoperative ARFI score and postoperative SRLV was: SRLV(ml/m2) = 149. 6 × ARFI score(m/s) + 194. 1. Preoperative urinary 8-OHdG level was significantly higher than that of the control group [(16. 15 ± 4. 96) ng/mg Cr vs (12. 13 ± 4. 66) ng/mg Cr]. Conclusion The specific inhibitors of COX-2/PGE2 pathway,meloxicam or celecoxib can significantly enhance the drug sensitivity of liver cancer molecular targeted drug sorafenib. PEG-SS-PLL/siVEGF may be applied to the anti-angiogenesis gene therapy of hepatocellular carcinoma. Combining SRLV with the detection of hepatic fibrosis degress has important guiding value for the primary hepatocellular carcinoma patients receiving preoperative assessment of the amount of liver resection. For the cases of medium or severe liver fibrosis,the safety of SRLV threshold is 503 ml/m2. Urinary 8-OHdG has high application value in the diagnosis and treatment of liver cancer.
Keywords：Hypoxia inducible factor 2 alpha(HIF-2α)N(e) -benzyloxy carbonyl -l-lysineVascular endothelial growth factor (VEGF)Standard residual liver volume (SRLV)8- hydroxydeoxyguanosineCyclooxygenase-2
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 418-423 )